<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140242</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-2DAUNO-058</org_study_id>
    <nct_id>NCT02140242</nct_id>
  </id_info>
  <brief_title>Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML</brief_title>
  <acronym>DaunoDouble</acronym>
  <official_title>Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Dresden, Nationales Centrum für Tumorerkrankungen Dresden (NCT/UCC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed trial will address two clinically important questions for younger patients with&#xD;
      newly diagnosed acute myeloid leukemia (AML): the optimal dose of daunorubicin in induction&#xD;
      therapy and the necessity of a second induction cycle in patients with a good response after&#xD;
      the first induction. The primary endpoint is the rate of good responders. Secondary outcomes&#xD;
      will be relapse-free survival, overall survival and minimal residual disease kinetics.&#xD;
      Patients will be recruited in about 40 treatment centers of the Study Alliance Leukemia study&#xD;
      group over a period of 40 months. The results will be of great clinical relevance: First, the&#xD;
      study could facilitate the establishment or confirmation of the optimal daunorubicin dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first part of the trial, patients will be randomly assigned to receive either 90 mg/m2&#xD;
      or 60 mg/m2 daunorubicin in the first induction cycle in addition to standard dosed&#xD;
      cytarabine. Assuming a superiority of 90 mg/m2, 436 patients will be recruited. In the second&#xD;
      part of the trial, good responders will be randomized to receive either a second or no&#xD;
      further induction cycle. Assuming a non-inferiority of the single induction regarding the&#xD;
      rate of complete remissions, a number of 360 patients will be included in the second part.&#xD;
      Furthermore, in case of a non-inferiority of single versus double induction in good&#xD;
      responders, about half of all younger AML patients could be spared a second induction cycle,&#xD;
      leading to a reduction in treatment-related mortality, fewer days spent in hospital and&#xD;
      improved quality of life.&#xD;
&#xD;
      As a result of the preplanned interim analysis of part I, the sponsor decided to suspend&#xD;
      randomization in trial part I and to offer all patients the standard dose of 60 mg/m2&#xD;
      daunorubicin in both induction cycles (part I and II of the trial). Because of this an&#xD;
      Amendment was sent to and approved by regulatories and ethics comitee.&#xD;
&#xD;
      The inclusion age was raised to 65 years based on the current German treatment guidelines in&#xD;
      which patients up to the age of 65 are considered eligible for intensive induction&#xD;
      chemotherapy with DA60 [Onkopedia-Leitlinie 2017].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2014</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate after first induction</measure>
    <time_frame>day 15</time_frame>
    <description>To investigate whether a higher dose of daunorubicin in induction chemotherapy leads to an increase in hematological good responders defined as having &lt;5% myeloid blasts on day 15 after start of induction therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate complete remissions</measure>
    <time_frame>day 35 after final induction</time_frame>
    <description>To investigate whether the rate of complete remissions (CR) after single induction is similar to that after double induction in patients with good response to induction I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate cytogenetic and molecular complete remissions</measure>
    <time_frame>day 35</time_frame>
    <description>To investigate whether a higher dose of daunorubicin in induction chemotherapy will lead to an increase in cytogenetic and molecular complete remissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To investigate whether a higher dose of daunorubicin will lead to improved event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). To investigate whether EFS, RFS and OS are similar after single versus double induction in patients with good response to induction I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival (RFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To investigate whether a higher dose of daunorubicin will lead to improved event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). To investigate whether EFS, RFS and OS are similar after single versus double induction in patients with good response to induction I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>To investigate whether a higher dose of daunorubicin will lead to improved event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). To investigate whether EFS, RFS and OS are similar after single versus double induction in patients with good response to induction I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between Minimal Residual Disease (MRD) and EFS, RFS, OS</measure>
    <time_frame>day 35</time_frame>
    <description>To correlate the level of cytogenetic and molecular minimal residual disease after induction treatment with survival outcomes EFS, RFS and OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of induction deaths</measure>
    <time_frame>day 60</time_frame>
    <description>Rate of induction deaths (until day 60 or beginning of consolidation treatment - whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infectious complications</measure>
    <time_frame>day 35</time_frame>
    <description>Incidence of serious infectious complications Grades 3-4 (Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sonographic cardiac left ventricular ejection fraction</measure>
    <time_frame>day 35</time_frame>
    <description>Sonographic cardiac left ventricular ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pro-brain natriuretic peptide (por-BNP) and Troponin-T</measure>
    <time_frame>day 35</time_frame>
    <description>Serum levels of pro-BNP and Trop-T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CTCAE grade ≥3 cardiac complications</measure>
    <time_frame>day 35</time_frame>
    <description>Incidence of CTCAE grade ≥3 cardiac complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early deaths</measure>
    <time_frame>week 2</time_frame>
    <description>Rate of early deaths (2 weeks)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <arm_group>
    <arm_group_label>daunorubicin 60 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study part 2: induction cycles double induction (only patients with good response)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study part 2: induction cycles single induction (only patients with good response)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>study part 1 - dose daunorubicin</intervention_name>
    <description>standard induction dose of daunorubicin 60 mg/m2 on days 3-5</description>
    <arm_group_label>daunorubicin 60 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>induction cycles</intervention_name>
    <description>single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.</description>
    <arm_group_label>Double induction</arm_group_label>
    <arm_group_label>Single induction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO&#xD;
             criteria, i.e. bone marrow aspirate or biopsy must contain ≥20% blasts of all&#xD;
             nucleated cells or differential blood count must contain ≥20% blasts. In acute&#xD;
             erythroid leukemia, ≥20% blasts in all non-erythroid bone marrow cells. In AML defined&#xD;
             by cytogenetic aberrations, the rate of blasts may be &lt;20%. Secondary AMLs are&#xD;
             eligible for inclusion.&#xD;
&#xD;
          -  Age 18- inkl.65 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Adequate liver and renal function as assessed by the following laboratory requirements&#xD;
             to be conducted within 7 days prior to screening:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times the upper limit of normal&#xD;
&#xD;
               -  alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 times upper&#xD;
                  limit of normal&#xD;
&#xD;
               -  Creatinine ≤ 1.5 times upper limit of normalExclusion Criteria:&#xD;
&#xD;
          -  Adequate cardiac function, i.e. left ventricular ejection fraction (LVEF) of ≥ 50% as&#xD;
             assessed by transthoracic two-dimensional echocardiography (&quot;M Mode&quot;) or multiple&#xD;
             gated acquisition scan (MUGA scan)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Women must fulfill at least one of the following criteria in order to be eligible for&#xD;
             trial inclusion:&#xD;
&#xD;
               -  Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with&#xD;
                  Serum follicle stimulating hormone (FSH) &gt; 40 U/ml)&#xD;
&#xD;
               -  Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without&#xD;
                  hysterectomy&#xD;
&#xD;
               -  Continuous and correct application of a contraception method with a Pearl Index&#xD;
                  of &lt;1% (e.g. implants, depots, oral contraceptives, intrauterine device - IUD).&#xD;
&#xD;
               -  Sexual abstinence&#xD;
&#xD;
               -  Vasectomy of the sexual partner&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients who are not eligible for standard chemotherapy as assessed by the treating&#xD;
             physician&#xD;
&#xD;
          -  Central nervous system manifestation of AML&#xD;
&#xD;
          -  Cardiac disease: i.e. heart failure New York Heart Association (NYHA) III or IV;&#xD;
             unstable coronary artery disease (MI more than 6 months prior to study entry is&#xD;
             permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
          -  Patients undergoing renal dialysis&#xD;
&#xD;
          -  Chronic pulmonary disease with clinical relevant hypoxia&#xD;
&#xD;
          -  Known HIV or Hepatitis infection&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Medical conditions other than AML with an estimated life expectancy below 6 months&#xD;
&#xD;
          -  Previous treatment of AML except hydroxyurea up to 5 days&#xD;
&#xD;
          -  Relapsed or primary refractory AML&#xD;
&#xD;
          -  Acute promyelocytic leukemia&#xD;
&#xD;
          -  Previous anthracycline-containing chemotherapy&#xD;
&#xD;
          -  Treatment with any known non-marketed drug substance or experimental therapy within 4&#xD;
             weeks prior to enrollment&#xD;
&#xD;
          -  Incapability of understanding purpose and possible consequences of the trial&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Evidence suggesting that the patient is not likely to follow the study protocol (e.g.&#xD;
             lacking compliance)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Röllig, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annett Haake</last_name>
    <phone>+049 - 0351 458 3965</phone>
    <email>annett.haake@ukdd.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Fiebig</last_name>
    <phone>+049 - 0351 458 5198</phone>
    <email>frank.fiebig@ukdd.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Interní klinika LF Masarykovy univerzity a Fakultní nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Hradec Králové, II. Clinic of international medicine</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ústav hematologie a krevní transfuze (ÚHKT)</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Jost, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH</name>
      <address>
        <city>Altenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Schulz-Abelius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rank, PD MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg Klinikum am Bruderwald</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Teichmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Rieger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Fuhrmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Görner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta Kliniken Bochum Hattingen</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Behringer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ev. Diakonie-Krankenhaus gGmbH Bremen</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Kullmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl.Thiem-Klinikum Cottbus gGmbH</name>
      <address>
        <city>Cottbus</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schmidt-Hieber, PD MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Röllig, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Düren gem. GmbH</name>
      <address>
        <city>Düren</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Flaßhove, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Düsseldorf GmbH</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aristoteles Giagounidis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Krause, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Noppeney, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Steffen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Dierks, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Hamm</name>
      <address>
        <city>Hamm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Krämer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Kaiser, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Scholl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Held, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Buske, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum Mittelrhein GmbH</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Niemann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Kayser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Neubauer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schliemann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg-Nord</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Schäfer-Eckart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakoniekrankenhaus Rotenburg</name>
      <address>
        <city>Rotenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall gGmbH</name>
      <address>
        <city>Schwäbisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Geer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Böblingen</name>
      <address>
        <city>Sindelfingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaufmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum Winnenden</name>
      <address>
        <city>Winnenden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefani Parmentier, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sal-aml.org/ueber-uns/einfuehrung-ueberblick</url>
    <description>study alliance</description>
  </link>
  <link>
    <url>http://www.uniklinikum-dresden.de/</url>
    <description>University Hospital</description>
  </link>
  <link>
    <url>http://www.czecrin.net/</url>
    <description>czech ECRIN center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>leukemia</keyword>
  <keyword>induction treatment</keyword>
  <keyword>daunorubicin</keyword>
  <keyword>7+3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

